Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.45
- Piotroski Score 6.00
- Grade Overweight
- Symbol (TMDX)
- Company TransMedics Group, Inc.
- Price $85.52
- Changes Percentage (-0.96%)
- Change -$0.83
- Day Low $84.63
- Day High $88.84
- Year High $177.37
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/24/2025
- Fiscal Year End N/A
- Average Stock Price Target $135.00
- High Stock Price Target $180.00
- Low Stock Price Target $45.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.35
- Trailing P/E Ratio -391.94
- Forward P/E Ratio -391.94
- P/E Growth -391.94
- Net Income $-25,028,000
Income Statement
Quarterly
Annual
Latest News of TMDX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TransMedics Group Inc (TMDX) Q3 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
The company forecasts revenue of $425 million to $445 million for the year, expecting growth of 76% to 84%. CEO Waleed Hassanein expressed confidence in the guidance, citing normalization in dynamics ...
By Yahoo! Finance | 1 week ago -
Here's Why TransMedics Group (TMDX) Rose in Q2
Carillon Tower Advisers' Carillon Eagle Small Cap Growth Fund Q2 2024 investor letter discusses small-cap stock performance. It highlights TransMedics Group, Inc. (NASDAQ:TMDX) as a top pick, with str...
By Yahoo! Finance | 2 months ago -
TransMedics Group, Inc. (TMDX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Oppenheimer's Favorite Stocks for the Next 12 Months includes TransMedics Group, Inc. (NASDAQ:TMDX) as a top pick. The company specializes in organ transplant services and logistics, with potential gr...
By Yahoo! Finance | 2 months ago
